Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Loading HALO News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||1.73%||84.86||1.8%||$758.98m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.65%||358.50||3.1%||$334.14m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.57%||118.59||2.5%||$316.39m|
|VRTX||Vertex Pharmaceuticals Incorporated||2.00%||87.74||2.6%||$136.56m|
|BMRN||BioMarin Pharmaceutical Inc.||4.60%||81.38||4.0%||$134.91m|
|SRPT||Sarepta Therapeutics, Inc.||6.19%||20.25||49.4%||$110.63m|
|A||Agilent Technologies, Inc.||0.56%||44.61||1.0%||$104.97m|
|EXAS||Exact Sciences Corporation||0.49%||12.31||21.4%||$102.72m|
|ACAD||ACADIA Pharmaceuticals Inc.||5.51%||34.25||19.6%||$100.96m|
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel oncology therapies that target the tumor microenvironment. Its investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. Halozyme Therapeutics was founded by Gregory Ian Frost in 1998 and is headquartered in San Diego, CA.